Tipichnye oshibki pri lechenii khronicheskoy serdechnoy nedostatochnosti so snizhennoy sistolicheskoy funktsiey serdtsa u detey


如何引用文章

全文:

开放存取 开放存取
受限制的访问 ##reader.subscriptionAccessGranted##
受限制的访问 订阅或者付费存取

详细

The article presents the current recommendations for the management of patients with chronic heart failure (CHF) in pediatric practice. The importance of non-medical treatment of CHF (stabilization of fluid balance, weight control, graduated exercise and etc.) is emphasized, and ignoring of this type of treatment makes it difficult to achieve the ultimate success and reduces the effectiveness of therapeutic interventions. The basic principles of drug therapy of CHF aimed at improving of myocardial contractility, reducing the load on the heart muscle, correction of electrolyte balance and acid-base balance, prevention and treatment of thromboembolic syndrome, and treatment of cardiac arrhythmias and cardiac conduction defect are discussed. It is emphasized that low adherence of practitioners to existing clinical guidelines negatively affects the quality and effectiveness of therapy for CHF in children; and clear and strict observance of guidelines allows to avoid the tactical mistakes in the management of patients with CHF and achieve better results.

全文:

受限制的访问

参考

  1. Guidelines for the diagnosis and treatment of Chronic Heart Failure: full text (update 2005). The Task Force for the diagnosis and treatment of CHF of the European Society of Cardiology. Eur. Heart J. 2005; 26(22): 2472.
  2. Скворцова В.А., Боровик Т.Э., Баканов М.И., и др. Нарушения питания у детей раннего возраста и возможности их коррекции. Вопросы современной педиатрии. 2011; 10(4): 119-25.
  3. Cowie M.R., Mosterd A., Wood D.A., et al. The epidemiology of heart failure. Eur. Heart J. 1997; 18(2): 208-25.
  4. Spencer F.A., Meyer T.E., Goldberg R.J. Twenty year trends (1975-1995) in the incidence, inhospital and long-term death rates associated with heart failure complicating acute myocardial infarction. J. Am. Coll. Cardiol. 1999; 34 (5): 1378-87.
  5. Khand A., Gemmel I., Clark A.L., Cleland J.G.F. Is the prognosis of heart failure improving? J. Am. Coll. Cardiol. 2000; 36(7): 2284-86.
  6. Мареев В.Ю., Агеев Ф.Т., Арутюнов Г.П. и др. Национальные рекомендации ВНОК и ОССН по диагностике и лечению ХСН (третий пересмотр). Сердечная недостаточность. 2013; 14(81): 379-472.
  7. Garg R., Yusuf S. Overview of randomized trials of angiotensin-converting enzyme inhibitors on mortality and morbidity in patients with heart failure. JAMA 1995; 273: 1450-56.
  8. Басаргина Е.Н., Белова Н.Р. Непосредственные и отдаленные результаты комплексного лечения ДКМП у детей. Вестник РАМН. 2008; 12: 52-6.
  9. Березнева Н.А., Арсеньева Е.Н., Басаргина Е.Н., Пинелис В.Г. Эффективность терапии сердечной недостаточности и состояние ренин-ангиотензин-альдостероновой системы у детей с дилатационной кардиомиопатией и врожденными пороками сердца. Детские болезни сердца и сосудов. 2011; 3.
  10. Басаргина Е.Н. Современный взгляд на лечение ХСН у детей. Российский педиатрический журнал. 2008; 1: 46-52.
  11. Khalil А., Chawla К., Chakravarti А. Dilated Cardiomyopathy: Clinical Profile and Tritment. Ind. Pediatr. 2000; 37: 1242-48.
  12. Luma G.B., Spoitta R.T. Hypertension in children and adolescents. J. Am. Family Physician. 2006; 73(9): 3-10.
  13. Kovacikova L., Kunovsky P., Skrak P., Haviar D., Martanovie H. Renovascular Hypertension in infant presenting with Cardiogenic Shock. Pediatr. Emerg. Care. 2005: 5(21): 322-24.
  14. NelsonTextbook of Pediatrics, 17th Edition. Edited by Behrman R.E., Kliegman R.M., Jenson H.B., 2004. 2618 p.
  15. Мареев В.Ю., Агеев Ф.Т., Арутюнов Г.П. и др. Национальные рекомендации ВНОК и ОССН по диагностике и лечению ХСН (третий пересмотр). Сердечная недостаточность. 2010; 11(1): 2-62.
  16. Lopez-Sendon J., Swedberg K., McMurray J., et al. Task Force on ACE-inhibitors of the European Society of Cardiology. Expert consensus document on angiotensin converting enzyme inhibitors in cardiovascular disease. The Task Force on ACE-inhibitors of the European Society of Cardblogy. Eur. Heart J. 2004; 25: 1454-70.
  17. Басаргина Е.Н., Леонтьева И.В., Котлукова Н.П. и др. Диагностика и лечение ХСН у детей. Методические рекомендации Ассоциации детских кардиологов России, М., 2010. 80 c.
  18. Клинические рекомендации по детской кардиологии и ревматологии. Под ред. М.А. Школьниковой, Е.И. Алексеевой. М., ООО М-Арт, 2011. С. 242-74.
  19. Willenheimer R., van Veldhuisen D.J., Silke B., et al. CIBIS III Investigators. Effect on survival and hospitalization of initiating treatment for chronic heart failure with bisoprolol followed by enalapril, ascompared with the opposite sequence: results of the randomized Cardiac Insufficiency Bisoprolol Study (CIBIS) III. Circulation. 2005; 112(16): 2426-35.
  20. Zannad F., Alla F., Dousset B., et al. Limitation of excessive extracellular matrix turnover may contribute to survival benefit of spironolactone therapy in patients with congestive heart failure. Insights from Randomized Aldactone Evaluation Study (RALES). Circulation. 2000; 102(22): 2700-706.
  21. Udelson J.E., Feldman A.M., Greenberg B., et al. Randomized, doubleblind, multicenter, placebo-controlled study evaluating the effect of aldosterone antagonism with eplerenone on ventricular remodelingin patients with mild-to-moderate heart failure and left ventricular systolic dysfunction. Circ. Heart Fail. 2010; 3(3): 347-53.
  22. Kramer D.G., Trikalinos T.A., Kent D.M., et al. Quantitative evaluation of drug or device effects on ventricular remodeling as predictors of therapeutic effects on mortality in patients with heart failure and reduced ejection fraction: a meta-analytic approach. J. Am. Coll. Cardiol. 2010; 56(5): 392-406.
  23. Li X., Qi Y., Li Y., et al. Impact of mineralocorticoid receptor antagonists on changes in cardiac structure and function of left ventricular dysfunction: a meta-analysis of randomized controlled trials. Circ. Heart Fail. 2013; 6(2): 156-65.
  24. Phelan D., Thavendiranathan P., Collier P., Marwick T.H. Aldosterone antagonists improve ejection fraction and functional capacity independently of functional class: a meta-analysis of randomised controlled trials. Heart. 2012; 98(23): 1693-700.
  25. Dickstein K., Cohen-Solal A., Filippatos G., et al.; ESC Committee for Practice Guidelines (CPG). ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: the Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2008 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association of the ESC (HFA) and endorsed by the European Society of Intensive Care Medicine (ESICM). Eur. Heart J. 2008; 29(19): 2388-442.
  26. Yamato M., Sasaki T., Honda K., et al. Effects of torasemide on left ventricular function and neurohumoral factors in patients with chronic heart failure. Circ. J. 2003; 67(5): 384-90.

补充文件

附件文件
动作
1. JATS XML
下载

版权所有 © Bionika Media, 2014
##common.cookie##